Skip to content
Catalyst

Coffea arabicaFinding

Coffea arabica has no detected effect on adverse event occurrence (oral or enteral supplement)

no difference foundModerate evidenceFinding

01 · The sentence it was drawn from

“No adverse symptoms were observed in either the study group or the control group during the study (Table 3).”
Quoted verbatim from Twelve-Week Safety and Potential Lipid Control Efficacy of Coffee Cherry Pulp Juice Concentrate in Healthy Volunteers.
This finding among the 11 findings on its endpoint

Coffea arabica

Adverse event occurrence (oral or enteral supplement)

no difference found

Who
Healthy adults aged 20 to 55, 12 weeks of daily consumption plus 2 weeks of follow-up
Dose studied
14 g sachet twice daily (28 g/day), 12 weeks

Moderate evidencePMID 37049443 · 2023

02 · The study

Study
RCT
Duration
3 months

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

03 · The paper

Nutrients
What else it reported3 findings · 0 compounds · 3 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZKPVNKVHSAYWYSD63RV3ZZ